Is Becton, Dickinson and Company a good investment?
Becton, Dickinson and Company (BDX) is currently trading at 209.19 USD.
Market analysts have a consensus price target of 195.57 USD.
This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 46.02.
This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule:
Becton, Dickinson and Company is expected to release its next earnings report on Nov. 5, 2026.
The market consensus estimate for Forward EPS is 13.30.
For income investors, Becton, Dickinson and Company pays a dividend yield of 1.90%.
With a payout ratio of 187%, the dividend appears
to be under pressure.
Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Community Discussion